The group management team is responsible for the strategic direction and overall performance of the entire group, which includes Atlas Antibodies, evitria, and HistoCyte. This team of experienced leaders oversees our corporate strategy, financial governance, and long-term vision, ensuring cohesive growth and success across all our business areas.
Ingela, CEO of Atlas Antibodies, brings over 15 years of experience in business transformation to Atlas from senior leadership roles at SAS and Scania. A specialist in operational excellence using Lean principles, she holds an M.Sc. in Economics and Business Administration from the Stockholm School of Economics.
Colin, CEO of HistoCyte, has over two decades of experience in the in vitro diagnostics field. His career began in antibody development at Novocastra (now Leica Biosystems), where he later moved into global sales, marketing, and innovation for advanced staining. In 2012, he leveraged this experience to co-found HistoCyte Laboratories, a company specializing in IHC/ISH cell-based controls.
Dr. Stefan Schmidt, CEO of evitria, brings over 25 years of executive experience in biologics development and manufacturing. Prior to this, he was COO at BioAtrium (a Lonza/Sanofi JV). He has also served as Chief Scientific Officer at Rentschler Biopharma and ERA Biotech and led Protein Sciences at AstraZeneca. Dr. Schmidt holds a PhD in Biochemistry and an MBA.
Albert is the Group Chief Financial Officer (CFO), where he is responsible for the financial strategy and performance of the group. He brings extensive financial leadership experience from the life science and media industries, having held senior finance roles at Viaplay, MTG, Peptonic and Deloitte.
Jacqueline is the Group Chief Commercial Officer (CCO), responsible for the group's commercial strategy and global growth. She brings extensive experience from the life science and technology sectors, with previous leadership roles at Abcam, DoubleClick, and E*TRADE.